531592 — Genpharmasec Income Statement
0.000.00%
- IN₹869.34m
- IN₹928.16m
- IN₹337.22m
- 38
- 33
- 11
- 13
Annual income statement for Genpharmasec, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 213 | 273 | 255 | 304 | 337 |
| Cost of Revenue | |||||
| Gross Profit | 21.1 | 7.55 | 21.2 | 61.7 | 41.7 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 201 | 279 | 253 | 304 | 345 |
| Operating Profit | 11.8 | -5.36 | 2.37 | 0.039 | -7.47 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 15.1 | -4.43 | 2.82 | 2.51 | 18.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 12.6 | -2.09 | 11.2 | -1.69 | 12.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 12.6 | -2.09 | 11.2 | -1.26 | 12.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 12.6 | -2.09 | 11.2 | -1.26 | 12.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.027 | -0.005 | 0.024 | -0.004 | 0.022 |